Search

Nominate yourself

You can nominate yourself for an EHA Board role as long as you have:

Any type of EHA membership apart from healthcare-affiliated membership
Paid your annual membership fees
If you're unsure how to pay your annual membership fees, visit our renew your membership…

Read more

Meeting Program

All times are in GMT-3, local time in Brazil.

Read more

Publications

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Leuk Res. 2017 Oct;61:6-9. doi: 10. 1016/j. leukres. 2017. 08. 002.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

Meeting program

Saturday, November 4*All times are in EET.

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

Navigate hematology

Building a career and a professional network can be overwhelming! Which career path should you take? How can you establish a meaningful mentoring relationship? Which funding is available and right for you? Who can you collaborate with? Is it time to publish?

On…

Read more